ArticleJournal of gynecologic oncology2026
Does delayed surgery affect survival in recurrent ovarian adult-type granulosa cell tumor? A retrospective study from a high-volume medical center.
Article in Journal of gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo evaluate the clinical characteristics, treatment outcomes, and the impact of delayed debulking surgery in recurrent adult-type granulosa cell tumors (AGCTs).
methodsThis retrospective cohort study analyzed patients diagnosed with recurrent AGCT between January 2003 and December 2023 at Peking Union Medical College Hospital. Kaplan-Meier analysis, along with univariate and multivariate Cox proportional hazards models, were utilized to identify factors associated with progression-free survival following the first, second, and third recurrences, as well as overall survival (OS).
resultsThe study included 92 patients with recurrent AGCT, with approximately 90% of tumors initially staged as stage I. The median follow-up time was 136.0 months (range, 30.0-402.0 months). Extra-pelvic and multifocal lesions were common in recurrent cases. Most patients underwent tumor cytoreductive surgery (CRS) at each recurrence. A time interval from recurrence to CRS of ≥6 months had no adverse impact on OS (multivariate hazard ratio [HR]=1.53; 95% confidence interval [CI]=0.33-7.05; p=0.582), but significantly prolonged the interval between relapses after the first (median interval not reached in the ≥6-month group vs. 40.0 months in the <6-month group; log-rank p=0.023) and second recurrence (median interval, 65.0 vs. 25.0 months; log-rank p<0.001). Gross residual disease after CRS was associated with poorer OS (multivariate HR=7.44; 95% CI=1.95-28.46; p=0.003).
conclusionDelaying CRS by ≥6 months can prolong the time to the next recurrence without compromising OS, while gross residual disease remains an independent risk factor for poor survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.